Arthur T. Sands
2021 - Nurix Therapeutics
In 2021, Arthur T. Sands earned a total compensation of $4.8M as President, Chief Executive Officer and Director at Nurix Therapeutics, a 72% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $297,000 |
|---|---|
| Option Awards | $3,948,993 |
| Salary | $538,750 |
| Other | $6,723 |
| Total | $4,791,466 |
Sands received $3.9M in option awards, accounting for 82% of the total pay in 2021.
Sands also received $297K in non-equity incentive plan, $538.8K in salary and $6.7K in other compensation.
Rankings
In 2021, Arthur T. Sands' compensation ranked 2,753rd out of 12,405 executives tracked by ExecPay. In other words, Sands earned more than 77.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,753 out of 12,405 | 78th |
Division Manufacturing | 1,090 out of 5,494 | 80th |
Major group Chemicals And Allied Products | 428 out of 2,369 | 82nd |
Industry group Drugs | 373 out of 2,090 | 82nd |
Industry Pharmaceutical Preparations | 249 out of 1,537 | 84th |
Source: SEC filing on March 25, 2022.
Sands' colleagues
We found four more compensation records of executives who worked with Arthur T. Sands at Nurix Therapeutics in 2021.
News
Nurix Therapeutics CEO Arthur Sands' 2023 pay falls 54% to $4.4M
March 27, 2024
Nurix Therapeutics CEO Arthur Sands' 2022 pay jumps 97% to $9.4M
March 24, 2023
Nurix Therapeutics COO Stefani Wolff receives $7.1M in 2021
March 25, 2022
Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M
March 25, 2021